Your browser doesn't support javascript.
loading
Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
Nishimura, Tadashi; Fujimoto, Hajime; Okano, Tomohito; Naito, Masahiro; Tsuji, Chikashi; Iwanaka, Soichi; Sakakura, Yasumasa; Yasuma, Taro; D'Alessandro-Gabazza, Corina N; Oomoto, Yasuhiro; Gabazza, Esteban C; Kobayashi, Tetsu; Ibata, Hidenori.
Afiliación
  • Nishimura T; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu City 514-1101, Japan.
  • Fujimoto H; Department of Pulmonary and Critical Care Medicine, Graduate School of Medicine, Mie University, Tsu City 514-8507, Japan.
  • Okano T; Department of Pulmonary and Critical Care Medicine, Graduate School of Medicine, Mie University, Tsu City 514-8507, Japan.
  • Naito M; Department of Pulmonary and Critical Care Medicine, Graduate School of Medicine, Mie University, Tsu City 514-8507, Japan.
  • Tsuji C; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu City 514-1101, Japan.
  • Iwanaka S; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu City 514-1101, Japan.
  • Sakakura Y; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu City 514-1101, Japan.
  • Yasuma T; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu City 514-1101, Japan.
  • D'Alessandro-Gabazza CN; Department of Immunology, Graduate School of Medicine, Mie University, Tsu City 514-8507, Japan.
  • Oomoto Y; Department of Immunology, Graduate School of Medicine, Mie University, Tsu City 514-8507, Japan.
  • Gabazza EC; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu City 514-1101, Japan.
  • Kobayashi T; Department of Immunology, Graduate School of Medicine, Mie University, Tsu City 514-8507, Japan.
  • Ibata H; Department of Pulmonary and Critical Care Medicine, Graduate School of Medicine, Mie University, Tsu City 514-8507, Japan.
Cancers (Basel) ; 14(12)2022 Jun 16.
Article en En | MEDLINE | ID: mdl-35740634
Reports on the efficacy of second-line treatment with cytotoxic agents after treatment with immune checkpoint inhibitors are limited. Here, we retrospectively evaluated patients in the real-world clinical practice treated with docetaxel or docetaxel plus ramucirumab. Ninety-three patients treated with docetaxel or docetaxel plus ramucirumab as a second- or later-line therapy were included. The patients were categorized into the following four treatment groups: docetaxel group (n = 50), docetaxel/ramucirumab group (n = 43) and pretreated (n = 45) and untreated (n = 48) with immune checkpoint inhibitor groups. The docetaxel/ramucirumab group showed an overall response rate of 57.1% in patients pretreated with immune checkpoint inhibitors and 20% in untreated patients. The docetaxel group showed an overall response rate of 15.4% in patients pretreated with immune checkpoint inhibitors and 5.0% in untreated patients. The median time-to-treatment failure and the median survival time were longer in the docetaxel/ramucirumab group than in the docetaxel group in both immune checkpoint inhibitor-pretreated and -untreated groups. There was no difference in time-to-treatment failure and overall survival between immune checkpoint inhibitor-pretreated and -untreated groups in each docetaxel and docetaxel/ramucirumab treatment group. In conclusion, our real-world data show that the addition of ramucirumab to docetaxel was superior to docetaxel monotherapy for improving time-to-treatment failure and overall survival, irrespective of previous treatment with immune checkpoint inhibitors.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Japón
...